January 5, 2024

selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024

June 2, 2023

selectION awaits efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis

May 30, 2023

selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis

November 29, 2022

Immusoft Receives $4M In Funding From The California Institute For Regenerative Medicine (CIRM)

October 17, 2022

Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer

September 12, 2022

selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients

September 1, 2022

Immusoft Announces FDA Clearance Of IND Application For ISP-001 For MPS I, The First Engineered B Cell Therapy To Enter Into Clinical Trials

May 9, 2022

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

October 19, 2021

Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

October 13, 2021

Immusoft And Takeda Collaborate To Discover And Develop Cell Therapies For Rare Neurometabolic Disorders